Olmesartan Studies Show “No Clear Evidence” Of CV Risk In Diabetes Patients, FDA Finds
This article was originally published in The Pink Sheet Daily
Executive Summary
Although data raise “concern of possible increased CV risk” with use of high-dose olmesartan in diabetic patients, FDA concludes that use of the drug in this group can continue.
You may also be interested in...
Public Citizen Asks US FDA To Ban Olmesartan Hypertension Medicines
Given risk of serious gastrointestinal disorder, Public Citizen argues there is no reason to keep the drugs on the market when so many alternative treatments are available
Pradaxa Medicare Study: Observing a Slow Attitude Change at FDA on Observational Studies
CDER Deputy Director Bob Temple is a confirmed skeptic of the value of observational trial data to FDA’s regulatory decisions. A recent Medicare study on the bleeding risks associated with Boehringer-Ingelheim’s Pradaxa, however, confirmed an earlier position on the drug by FDA and meets with Temple’s approbation.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.